Uprosertib hydrochloride is primarily used in research and development within the field of oncology. It functions as a potent and selective inhibitor of AKT, a protein kinase involved in cell signaling pathways that regulate cell survival, growth, and metabolism. By inhibiting AKT, this compound is investigated for its potential to halt the progression of various cancers, particularly those driven by hyperactive PI3K/AKT signaling pathways, such as breast, ovarian, and prostate cancers. Its application extends to preclinical studies aimed at understanding tumor biology and evaluating the efficacy of targeted therapies. Additionally, it serves as a tool compound in biochemical assays to explore the role of AKT in cellular processes and to develop novel therapeutic strategies for cancer treatment.